PT1296996E - Derivados de purina - Google Patents

Derivados de purina

Info

Publication number
PT1296996E
PT1296996E PT01938490T PT01938490T PT1296996E PT 1296996 E PT1296996 E PT 1296996E PT 01938490 T PT01938490 T PT 01938490T PT 01938490 T PT01938490 T PT 01938490T PT 1296996 E PT1296996 E PT 1296996E
Authority
PT
Portugal
Prior art keywords
purine derivatives
purine
derivatives
Prior art date
Application number
PT01938490T
Other languages
English (en)
Inventor
Sandra Marina Monaghan
Peter Thomas Stephenson
Simon John Mantell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT1296996E publication Critical patent/PT1296996E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
PT01938490T 2000-06-27 2001-06-14 Derivados de purina PT1296996E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0015727.1A GB0015727D0 (en) 2000-06-27 2000-06-27 Purine derivatives

Publications (1)

Publication Number Publication Date
PT1296996E true PT1296996E (pt) 2004-08-31

Family

ID=9894500

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01938490T PT1296996E (pt) 2000-06-27 2001-06-14 Derivados de purina

Country Status (42)

Country Link
EP (1) EP1296996B1 (pt)
JP (1) JP2004501929A (pt)
KR (1) KR20030036248A (pt)
CN (1) CN1432020A (pt)
AP (1) AP1372A (pt)
AR (1) AR028759A1 (pt)
AT (1) ATE267836T1 (pt)
AU (1) AU2001264164A1 (pt)
BG (1) BG107171A (pt)
BR (1) BR0111912A (pt)
CA (1) CA2412564C (pt)
CZ (1) CZ20023992A3 (pt)
DE (1) DE60103537T2 (pt)
DK (1) DK1296996T3 (pt)
DO (1) DOP2001000195A (pt)
EA (1) EA200201291A1 (pt)
EC (1) ECSP024396A (pt)
EE (1) EE200200712A (pt)
ES (1) ES2220775T3 (pt)
GB (1) GB0015727D0 (pt)
GT (1) GT200100119A (pt)
HR (1) HRP20020995A2 (pt)
HU (1) HUP0301389A3 (pt)
IL (1) IL152529A0 (pt)
IS (1) IS6580A (pt)
MA (1) MA26918A1 (pt)
MX (1) MXPA03000078A (pt)
NO (1) NO20025975D0 (pt)
NZ (1) NZ521867A (pt)
OA (1) OA12294A (pt)
PA (1) PA8521001A1 (pt)
PE (1) PE20020213A1 (pt)
PL (1) PL361384A1 (pt)
PT (1) PT1296996E (pt)
SI (1) SI1296996T1 (pt)
SK (1) SK17332002A3 (pt)
SV (1) SV2002000507A (pt)
TN (1) TNSN01096A1 (pt)
TR (1) TR200401622T4 (pt)
UY (1) UY26797A1 (pt)
WO (1) WO2002000676A1 (pt)
ZA (1) ZA200209557B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016307A1 (en) 2001-08-14 2003-02-27 Eli Lilly And Company β3 ADRENERGIC AGONISTS
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
EP1802316B1 (en) * 2004-09-20 2011-11-02 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
KR20080049113A (ko) 2005-10-21 2008-06-03 노파르티스 아게 Il-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ES2440317T3 (es) * 2006-04-21 2014-01-28 Novartis Ag Derivados de purina para su uso como agonistas del receptor de adenosina A2A
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
RU2009120389A (ru) 2006-10-30 2010-12-10 Новартис АГ (CH) Гетероциклические соединения в качестве противовоспалительных агентов
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
BRPI0915173B8 (pt) * 2008-06-11 2021-05-25 Agilent Technologies Inc compostos de nucleotídeos e nucleosídeos e método de sequenciamento de um ácido nucleico-alvo
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
SG178454A1 (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン, エルエルシー 複素環化合物およびその使用
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
IL107101A0 (en) * 1992-09-30 1993-12-28 Merrell Dow Pharma 2-substituted adenosines with a-2 receptor affinity
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
AU2108299A (en) * 1998-01-08 1999-07-26 University Of Virginia Patent Foundation A2A adenosine receptor agonists
EP1121372B1 (en) * 1998-10-16 2006-06-28 Pfizer Limited Adenine derivatives
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9924361D0 (en) * 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
BG107171A (en) 2003-07-31
UY26797A1 (es) 2002-01-31
DE60103537T2 (de) 2005-07-07
ZA200209557B (en) 2003-12-02
EA200201291A1 (ru) 2003-04-24
ATE267836T1 (de) 2004-06-15
NO20025975L (no) 2002-12-12
EP1296996A1 (en) 2003-04-02
CZ20023992A3 (cs) 2003-12-17
EP1296996B1 (en) 2004-05-26
MXPA03000078A (es) 2003-08-19
IS6580A (is) 2002-10-10
AR028759A1 (es) 2003-05-21
GB0015727D0 (en) 2000-08-16
PA8521001A1 (es) 2002-04-25
TR200401622T4 (tr) 2004-08-23
SI1296996T1 (en) 2004-10-31
WO2002000676A1 (en) 2002-01-03
CN1432020A (zh) 2003-07-23
PL361384A1 (en) 2004-10-04
SK17332002A3 (sk) 2004-03-02
DOP2001000195A (es) 2002-05-15
AU2001264164A1 (en) 2002-01-08
EE200200712A (et) 2004-06-15
TNSN01096A1 (fr) 2005-11-10
HUP0301389A2 (hu) 2003-08-28
CA2412564C (en) 2007-10-02
NO20025975D0 (no) 2002-12-12
DE60103537D1 (de) 2004-07-01
NZ521867A (en) 2004-04-30
HRP20020995A2 (en) 2005-02-28
DK1296996T3 (da) 2004-08-16
MA26918A1 (fr) 2004-12-20
OA12294A (en) 2003-11-14
ES2220775T3 (es) 2004-12-16
IL152529A0 (en) 2003-05-29
AP1372A (en) 2005-02-21
CA2412564A1 (en) 2002-01-03
SV2002000507A (es) 2002-07-03
HUP0301389A3 (en) 2005-02-28
GT200100119A (es) 2002-01-31
ECSP024396A (es) 2003-02-06
BR0111912A (pt) 2003-05-13
KR20030036248A (ko) 2003-05-09
JP2004501929A (ja) 2004-01-22
PE20020213A1 (es) 2002-03-19

Similar Documents

Publication Publication Date Title
PT1296996E (pt) Derivados de purina
PT1220863E (pt) Derivados de purina
ATE325807T1 (de) Purinderivate
ATE321065T1 (de) Purin-derivate
IS6196A (is) Púrín afleiður
ATE431356T1 (de) 2-aminocarbonyl-9h-purinderivative
ATE314072T1 (de) Antivirale azaindolderivate
GB0022695D0 (en) Purine Derivatives
PT1303521E (pt) Derivados de tetra-hidro-heterocicloazepinil-pirimidina
AR028602A1 (es) Derivados de pirrol
AR028282A1 (es) Derivados de aminofenil pirimidona
PT1246791E (pt) Derivados de aminometilfenilciclo-hexanona
GB0014048D0 (en) Purine derivatives
GB0024920D0 (en) Purine derivatives